Pliant Therapeutics Inc. Common Stock (PLRX)

About PLRX

Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors. It is also developing drug discovery platform comprising proprietary…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

49

Website

pliantrx.com/

Fundamentals

1-day range

$1.11$1.15

Market cap

$64.40M

P/E (trailing)

—

P/E (forward)

-0.83

EPS (trailing)

$-2.43

Dividend yield

—

Beta

1.30

Avg. volume

518.3K

Forecasts

2 analyst ratings

Pliant Therapeutics Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• PLRX

  Pliant Therapeutics Inc. Common Stock

  $1.11

  ▼ 3.48%
  Market cap $64.40MP/E —
  $1.02$1.95
• RNTX

  Rein Therapeutics Inc. Common Stock

  $0.7621

  ▼ 2.67%
  Market cap $63.77MP/E —
  $0.694$2.18
• CING

  Cingulate Inc. Common Stock

  $5.32

  ▼ 2.21%
  Market cap $65.06MP/E —
  $3.16$11.89
• MNOV

  Medicinova Inc Common Stock

  $1.44

  ▲ 1.05%
  Market cap $65.46MP/E —
  $1.17$1.96
• ELTX

  Elicio Therapeutics Inc. Common Stock

  $2.86

  ▼ 4.67%
  Market cap $65.84MP/E —
  $2.66$16
• SPRO

  Spero Therapeutics Inc. Common Stock

  $1.2

  ▼ 0.83%
  Market cap $66.59MP/E 4.73
  $1.08$3.08
• ACRV

  Acrivon Therapeutics Inc. Common Stock

  $2.06

  ▼ 4.19%
  Market cap $66.77MP/E —
  $1.27$3.56

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Pliant Therapeutics Receives Fast Track Designation From FDA For PLN-101095 In Combination With Pembrolizumab For Potential Treatment Of Solid Tumors
  benzinga · 8/18/2026
• Pliant Therapeutics Receives Fast Track Designation From FDA For PLN-101095 In Combination With Pembrolizumab For Potential Treatment Of Solid Tumors
  Benzinga · 8/18/2026
• Pliant Therapeutics Q2 EPS $(0.36) Misses $(0.34) Estimate
  Benzinga · 8/11/2026

• Flavia Borellini · July 9, 2026 · Grant

  60.0K
• Robert Iannone · July 9, 2026 · Grant

  60.0K
• Steve E. Krognes · June 11, 2026 · Grant

  70.0K
• Cline Darren S · June 11, 2026 · Grant

  70.0K
• Curnutte John T · June 11, 2026 · Grant

  70.0K
• MCCOURT Thomas A · June 11, 2026 · Grant

  70.0K
• Hoyoung Huh · June 11, 2026 · Grant

  70.0K
• CROWELL GAYLE A · June 11, 2026 · Grant

  70.0K
• Minnie Kuo · April 17, 2026 · Grant

  55.2K
• Minnie Kuo · April 17, 2026 · Disposition

  55.2K
• Minnie Kuo · April 17, 2026 · Grant

  40.0K
• Minnie Kuo · April 17, 2026 · Disposition

  40.0K
• Minnie Kuo · April 17, 2026 · Grant

  150.0K
• Minnie Kuo · April 17, 2026 · Disposition

  150.0K
• Keith Lamont Cummings · April 17, 2026 · Grant

  113.3K

Institutional Ownership

March 31, 2026

Total shares held

48.49M

Total value held

$56.71M

Institutional holders

87